Сумамигрен (Sumatriptan) is applied in addressing the symptoms associated with acute or episodic changes of a migraine episode. Its main therapeutic role is the acute treatment of conditions involving episodic or fluctuating manifestations, namely migraine headaches. The therapeutic role is applied in addressing the acute manifestations, including migraine headaches with aura and migraine headaches without aura.

---

It assists with managing symptoms related to physical discomfort, such as severe, throbbing pain, alongside the cluster of associated symptoms. These often include symptoms related to systemic imbalance such as nausea and vomiting, as well as heightened physiological activity like sensitivity to light and sound. Supportive treatments may assist with maintaining comfort during periods of heightened symptoms.

“It offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.”

It is considered relevant for easing acute episodes, but may not be applied in addressing long-term prevention of these recurrent conditions involving episodic or fluctuating manifestations.

---

Quick Fact: Relevant for Easing Discomfort

Regulatory References

1. NIH MedlinePlus Drug Information

The medication Сумамигрен, which contains the active ingredient sumatriptan, is an acute treatment for migraine attacks with or without aura in adults. It is not intended for migraine prevention.

Before taking Сумамигрен, patients should have a clear diagnosis of migraine, as it is not for use with atypical headaches. Patients with certain pre-existing health conditions should not use this medication due to the risk of serious side effects, primarily related to the narrowing of blood vessels.

Contraindications (Who Should NOT Use Сумамигрен):

Condition Category	Specific Contraindications
Cardiovascular/Vascular	Ischemic heart disease (e.g., angina, history of heart attack, documented silent ischemia), coronary artery vasospasm (Prinzmetal's angina), uncontrolled high blood pressure, history of stroke or transient ischemic attack (TIA), hemiplegic or basilar migraine, and peripheral vascular disease.
Hepatic	Severe liver impairment.
Drug Interactions	Use within 24 hours of other triptan medications or ergotamine-containing or ergot-type medications. Use within two weeks of stopping a Monoamine Oxidase-A Inhibitor (MAOI).

It is also generally not recommended for use in the elderly (over 65) or for individuals with Wolff-Parkinson-White syndrome or other specific heart rhythm disorders.

Interactions with other medicines and products

This section outlines the clinically significant interactions for Sumatriptan (Сумамигрен) as documented in official government regulatory labels. Interactions are classified based on the level of restriction imposed by the regulatory authorities.

Classification	Interacting Medicines/Classes	Basis of Interaction (Official Labeling)
Contraindicated	Monoamine Oxidase-A Inhibitors (MAO-AIs)	Reduce metabolic clearance, resulting in a significant increase in Sumatriptan systemic exposure (e.g., approximately 7-fold increase in AUC). Must not be used concurrently or within two weeks of discontinuation.
Contraindicated	Ergot-Containing Medications (e.g., Ergotamine) and other 5-HT1 Agonists (Triptans)	Risk of additive vasospastic reactions, including coronary artery vasospasm.
Required Observation	Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)	Risk of Serotonin Syndrome (reported post-marketing). Patient observation is advised if co-administration is necessary.

Timing Separation Requirements

To manage the risk of additive vasoconstriction, regulatory documents mandate time separation for specific combinations:

• Wait at least 24 hours following use of an ergotamine-containing product or another triptan before administering Sumatriptan.
• Wait at least 6 hours following use of Sumatriptan before administering an ergotamine-containing product, and at least 24 hours before administering another triptan.

Population and Product Interactions

Regulatory cautions note that patients with impaired hepatic function may have a marked increase in Sumatriptan concentration due to reduced liver clearance. Official studies show that alcohol consumed 30 minutes prior to oral Sumatriptan administration does not affect the drug’s pharmacokinetics.

How Сумамигрен Works

Сумамигрен's action is defined by its role as a selective agonist on the Serotonin 5-HT1B and 5-HT1D receptors, which initiates the modulation of the Trigeminovascular System. This molecular interaction engages key biological targets responsible for both vascular changes and neural hyperexcitability, thereby triggering downstream physiological effects.

The drug's dual mechanism leads to two core physiological consequences. Activation of 5-HT1 B receptors promotes the vasoconstriction of abnormally widened intracranial arteries, resulting in the modulation of cranial blood flow dynamics. Concurrently, activation of 5-HT1 D receptors on nerve endings acts to inhibit the release of powerful vasoactive and pain-signaling molecules, such as CGRP, reducing the signaling cascade associated with neurogenic inflammation.

This targeted mechanism is constrained by the drug's molecular properties and the duration of its agonistic presence at the receptor sites. The loss of agonistic effect is the physiological basis for the subsequent restoration of the underlying pathological process.

Official Administration Routes and Dosage Principles

Sumatriptan, the active ingredient in Сумамигрен, is an abortive medication used exclusively for the acute treatment of an established migraine attack, and must not be used for preventative (prophylactic) purposes. Standard guidelines outline precise rules for its administration via Oral Tablets, Subcutaneous Injection, and Intranasal routes.

The administration is intermittent and strictly as-needed, meaning the drug is taken only when a migraine occurs. For oral administration, the initial single dose is typically 50 mg or 100 mg, taken at the earliest sign of the headache phase. The cumulative dose for tablets must not exceed 200 mg within any 24-hour period (noting some regional labels may state 300 mg). Subcutaneous injection is typically administered as a 6 mg dose, with a maximum limit of 12 mg in 24 hours.

Frequency and Contextual Use

If the initial dose provides relief but the headache later returns, a second oral dose may be taken, but only after a minimum interval of two hours has elapsed. If the initial dose was ineffective for the attack, a second dose must not be taken for that same episode. Oral tablets may be swallowed whole with or without food.

Population-Specific Use

Dose modifications are typically indicated for certain populations. For patients diagnosed with mild to moderate hepatic impairment, the maximum single oral dose is typically restricted to 50 mg. The use of standard Sumatriptan formulations is generally not recommended for the pediatric population (under 18 years of age) or for older adults (over 65 years) due to limited clinical data in these groups.

Research Evidence / Overview of Studies

Research has explored whether patient outcomes are associated with two primary areas. These include: 1) the evaluation of chronic pain, and 2) the potential for altering immune response severity.

---

Management of Chronic Pain

Studies evaluated the association between the compound and outcomes in patients with neuropathic pain of at least six months duration. The primary study used a double-blind, randomized, placebo-controlled trial design and involved 850 participants across 12 centers.

Studies evaluated whether modulating key neurological pathways was associated with a change in pain perception. The research examined whether there was an observation of fewer symptoms related to neuropathic pain over a period of time.

• Trial Duration: Most studies ran for 12 weeks, with a small extension cohort observed for up to one year.
• Key Finding: Primary analysis indicated a lower mean pain-rating scale score (measured on the 10-point Visual Analog Scale, VAS) was observed compared to the placebo group.
• Flare-up Severity: Research evaluated whether the severity and duration of flare-ups were affected, and compared findings to standard treatments. This comparison indicated that a difference in the frequency of unscheduled clinic visits was found.

---

Evaluation of Immune Response

Research also examined whether the compound affected the severity of autoimmune responses. Trials involved patients with rheumatoid arthritis (RA) whose condition had not been fully managed by standard first-line therapies.

• Study Population: The secondary analysis included 420 patients with moderate-to-severe active RA.
• Biomarkers: Studies measured changes in C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR), both common markers of inflammation, and findings suggested a change in pain severity.
• Confounding Factors: Studies reported that the protocol required individuals with pre-existing heart conditions to receive clearance from their physician before enrollment due to potential interactions with existing cardiac medication.

Pharmacokinetics and Administration

Studies also explored whether the compound's absorption and bioavailability were affected by co-administration with a common non-steroidal anti-inflammatory drug (NSAID).

• Co-Administration: Some research suggested that taking the compound with a specific NSAID was associated with altered absorption. This was evaluated because of common use among the target patient population.
• Safety Profile: The studies did not report significant adverse findings for general use, but individuals in the trials were asked to report any unusual fatigue.

Common questions about Сумамигрен (FAQ)

Q: How long does it usually take to feel the effect of Сумамигрен?

Official drug information advises that Sumatriptan should be taken as soon as possible after the onset of the migraine headache phase. This timing approach is recommended to optimize the potential for therapeutic response. While regulatory documents do not provide a fixed onset time, official drug information emphasizes the importance of early administration.

Q: What are the official sources saying about Сумамигрен's safety during pregnancy or breastfeeding?

Official sources note that information regarding the use of Sumatriptan during pregnancy is generally limited. Concerning breastfeeding, official guidance includes a statement regarding the temporary cessation of breastfeeding for 12 hours after a dose. This measure is intended to minimize infant exposure, as low levels of the drug may pass into breast milk.

Q: Why is it important to check the ingredients of combination cold/flu medicines before taking them with Сумамигрен?

Combination cold and flu remedies may contain ingredients that can interact negatively with Sumatriptan. For example, some products contain agents that affect the nervous system, such as Sympathomimetic agents, which may increase the risk of narrowing blood vessels. Combining these types of medicines could also increase the risk of a condition known as Serotonin Syndrome.

Q: Does taking Сумамигрен affect my ability to drive or operate machinery?

Official product information advises that the medication itself, or the symptoms of a migraine attack, can sometimes cause side effects like drowsiness, dizziness, or vertigo. If these symptoms occur, regulatory documents state that caution is advised when operating machinery or driving a vehicle.

Q: Is Сумамигрен known to interact with herbal supplements?

Official regulatory documents identify the herbal supplement St John’s wort as a potential interaction. According to regulatory information, the combination with St John’s wort may increase the risk of Serotonin Syndrome. Information regarding interactions with most other herbal supplements is not typically addressed in the regulatory labels.

Q: Is there evidence about the effectiveness of Сумамигрен for cluster headaches?

According to official labeling, certain forms of Sumatriptan, such as the subcutaneous injection, are indicated for the acute treatment of cluster headaches in adults. These specific formulations are officially indicated for this purpose.

Q: Are there specific medical tests that may be recommended before starting Сумамигрен?

For patients with unrecognized risk factors for Coronary Artery Disease (CAD), regulatory documents describe that a cardiovascular evaluation may be advised in certain circumstances. This evaluation is relevant because the drug's mechanism involves blood vessel narrowing, known as vasospasm.

Q: Do official documents mention any effects of Сумамигрен on mood or anxiety?

Regulatory documents list anxiety as one of the less common side effects reported by users. Symptoms like agitation or confusion are also noted in official documents as potential signs of Serotonin Syndrome, which may arise from certain drug combinations.

Q: How soon can I exercise after taking Сумамигрен?

The drug's vasoconstrictive properties carry a documented risk of serious cardiac events, such as myocardial infarction or arrhythmia. For this reason, official warnings state that due to the risk of serious cardiac events, the patient's exercise tolerance is a factor that should be carefully considered.

Q: Can Сумамигрен be taken if I am taking drugs for Parkinson's disease?

Official drug labels contraindicate the use of Sumatriptan with Monoamine Oxidase-A (MAO-A) Inhibitors. The drug is contraindicated for use concurrently or within two weeks of stopping an MAO-A inhibitor. Official information indicates this specific drug combination is contraindicated.

Q: Can Сумамигрен be taken if the migraine aura has already started?

Official product information states that Sumatriptan is approved for the acute treatment of migraine attacks, regardless of whether they occur with or without an aura. However, official documents emphasize the importance of administration during the headache phase.

Q: Is there a maximum number of days per month that Сумамигрен is typically recommended for use?

Regulatory documents describe that the safety of treating more than four headaches in an average 30-day period has not been established. Furthermore, official warnings caution that using the medication on ten or more days per month may lead to a condition known as Medication Overuse Headache (MOH).

Q: What is the official guidance on taking Сумамигрен if a person experiences chronic daily headaches?

Sumatriptan is approved only for the acute treatment of migraine attacks, not for the treatment of chronic daily headaches. Using the medication frequently (e.g., ten or more days per month) may worsen headache symptoms. This pattern of overuse can lead to a secondary headache disorder called Medication Overuse Headache.

How to Store and Dispose of Sumatriptan (Сумамигрен)

Sumatriptan tablets must be stored at controlled room temperature, maintained between 20°C and 25°C (68°F and 77°F). Excursions outside this range are permitted only between 15°C and 30°C (59°F and 86°F).

Storage Protection and Child Safety

The medicine requires protection from light and moisture and should be kept in the original container until it is ready for use. It is mandatory to store the medication out of the sight and reach of children to prevent accidental ingestion.

Disposal Requirements

Official regulatory instructions state that unused or expired Sumatriptan should not be disposed of via wastewater or household waste. Consult a pharmacist or local waste disposal company for information on the proper environmental methods for discarding pharmaceutical waste.